Inimmune is a clinical-stage innovative biotech company focused on the discovery and development of novel, disruptive immunotherapies for allergy, cancer, infectious and autoimmune diseases. Our deep pipeline of clinical and pre-clinical assets as well as a strong intellectual property position is poised to change the landscape of immunotherapy. Our team has a long track record of success in discovering and developing new immunotherapies as standalone drugs and as vaccine adjuvants.
In July 2020, we announced the largest Series A investment in Montana history, a $22 million round led by Two Bear Capital out of Whitefish, MT. Mike Goguen, founder and managing partner of Two Bear and a 20 year veteran of Sequoia Capital commented, “The team at Inimmune combines world-class immunology and vaccine expertise, proven track records, and a passion for solving some of the most important medical crises of our time.”
We are actively seeking investors for our Series A extension round who share our vision to create and develop new, safe, and effective immunotherapeutics. Want to invest in improving human health?
